ArticleVeterinary research2025
Exploring the therapeutic potential of recombinant bovine β-defensins for antimicrobial and anti-inflammatory functions in sepsis management.
Article in Veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vitamin D and antimicrobial peptides in skin health and disease: Mechanisms and therapeutic potential.Biochemistry and biophysics reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
β-defensins are multifunctional peptides of the host immune system involved in responses to infectious diseases. We investigated the potential of five recombinant proteins based on bovine β-defensins (bovine neutrophil β-defensins (BNBD) 1, 2, 3, and 4, and the tracheal antimicrobial peptide (TAP)) in functions relevant to sepsis such as antimicrobial activity, lipopolysaccharide (LPS) binding and neutralisation, and the stimulation of cytokine response in epithelial cells. These β-defensins were produced in Lactococcus lactis as fusion proteins. Antimicrobial activity was tested against Escherichia coli; LPS binding and neutralisation were assessed using a fluorescent probe displacement assay and by measuring tumour necrosis factor alpha (TNFα) levels in whole blood after an LPS challenge, respectively. Interleukin-8 (IL-8) levels were quantified to evaluate the epithelial immune response. All β-defensins exhibited different properties, suggesting they may have distinct mechanisms and functions in resolving infections. The recombinant BNBD4 showed potent antimicrobial activity against E. coli, whereas TAP was more notable for its ability to bind and neutralise LPS. These findings suggest that β-defensins, particularly BNBD4 and TAP, may be utilised to treat sepsis by targeting bacterial pathogens and modulating inflammatory responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.